Search

everythinglearnresearchcommunity

for

Search:↓

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

The conversation discusses alternative hair loss treatments beyond the commonly used Minoxidil and Finasteride. One user is trying diclofenac gel, caffeine + antioxidant serum, finasteride, ketoconazole shampoo, and has stopped using Minoxidil due to ineffectiveness, while another user has adopted lifestyle changes like exercise, diet, stress reduction, and topical caffeine, along with scalp massages and microneedling.

The conversation discusses the difference in attitudes toward hair loss treatments, with a focus on lifestyle changes and hair transplant surgery in Hong Kong, as opposed to treatments like minoxidil, finasteride, and microneedling discussed on 'tresless'. The user is now using finasteride and minoxidil and considering microneedling.

A new hair loss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Hair loss treatments like finasteride, minoxidil, and hair transplants are more accessible and effective now. Concerns about side effects and skepticism about new treatments like hair cloning and GT20029 remain.

User tried Exosomes for hair loss with no success but experienced healing in other areas. Noticed people with previous hair transplants responded well to Exosomes.

Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.

A 27-year-old male is using a minoxidil and finasteride spray for hairline recession and is considering other treatments like oral minoxidil, exosomes, PRP, or a hair transplant. Suggestions include microneedling, possibly with tretinoin, while another user suggests the hairline is fine and mentions body dysmorphia.

A 19-year-old is concerned about long-term microneedling for hair loss and is unsure if it will remain effective as they age. They experienced side effects from topical finasteride and are considering whether to try it again in the future, while also dealing with body dysmorphia and stress.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.